Long-term impact of molecular response fluctuations in chronic myeloid leukaemia patients treated with imatinib

Br J Haematol. 2018 Apr;181(2):275-278. doi: 10.1111/bjh.14560. Epub 2017 Feb 17.
No abstract available

Keywords: chronic myeloid leukaemia; imatinib; molecular fluctuation; prognosis; resistance.

Publication types

  • Letter

MeSH terms

  • Female
  • Fusion Proteins, bcr-abl* / genetics
  • Fusion Proteins, bcr-abl* / metabolism
  • Humans
  • Imatinib Mesylate / administration & dosage*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / enzymology
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / genetics
  • Male
  • Middle Aged

Substances

  • BCR-ABL1 fusion protein, human
  • Imatinib Mesylate
  • Fusion Proteins, bcr-abl